Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.83 |
| ▸ | CD63 | P08962 | 6/20 | 0.83 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16820575 | 0.91 | SYK (1.00) | SYKCD63JAK2 | |
| SCHEMBL18996752 | 0.86 | SYK (0.83) | SYKCD63JAK2 | |
| SCHEMBL18996757 | 0.83 | SYK (0.86) | SYKCD63JAK2 | |
| SCHEMBL16820596 | 0.79 | SYK (0.78) | SYKCD63JAK2 | |
| SCHEMBL16820600 | 0.79 | SYK (0.78) | SYKCD63JAK2 | |
| Hydrochloric Acid SCHEMBL30850383 | 0.79 | SYK (0.78) | SYKCD63JAK2 | |
| Lanraplenib SCHEMBL29422916 | 0.77 | SYK (1.00) | SYKCD63JAK2 | |
| Lanraplenib SCHEMBL16820581 | 0.77 | SYK (1.00) | SYKCD63JAK2 | |
| SCHEMBL16848702 | 0.77 | SYK (0.81) | SYKCD63JAK2 | |
| SCHEMBL23470341 | 0.77 | SYK (0.86) | SYKCD63JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170173034-A1 | COMBINATION OF A JAK INHIBITOR AND A SYK INHIBITOR FOR TREATING CANCERS AND INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173034-A1 | COMBINATION OF A JAK INHIBITOR AND A SYK INHIBITOR FOR TREATING CANCERS AND INFLAMMATORY DISORDERS | SYK, BTK, JAK1 | SYK 1/4885CD63 2662/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.